Skip to main content
Journal cover image

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Publication ,  Journal Article
Evon, DM; Amador, J; Stewart, P; Reeve, BB; Lok, AS; Sterling, RK; Di Bisceglie, AM; Reau, N; Serper, M; Sarkar, S; Lim, JK; Golin, CE; Fried, MW
Published in: Aliment Pharmacol Ther
April 2018

BACKGROUND: To better understand symptoms experienced by patients infected with chronic hepatitis C virus (HCV), valid and reliable patient-reported outcome (PRO) measures are needed. AIM: To assess the reliability and validity of 10 patient-reported outcomes measurement information system (PROMIS) measures and the Headache Impact Test-6 (HIT-6) in a large national sample of patients with HCV. METHODS: Pre-treatment data from 961 patients with HCV starting direct acting antiviral therapy at 11 U.S. liver centers were analyzed. Internal reliability was evaluated using Cronbach's alpha coefficient; frequency distributions were examined for floor and ceiling effects; structural validity was investigated via item-response-theory models; convergent validity was evaluated using correlations with theoretically-similar items from the HCV-PRO and memorial symptom assessment scale (MSAS); and known-groups validity was investigated by observing PRO differences by liver disease status and number of comorbidities. RESULTS: The HIT-6 and the majority of the PROMIS measures yielded excellent reliability (alphas ≥ 0.87). Ceiling effects were infrequent ( < 4%), while 30%-59% of patients reported no symptoms (floor effects). The data supported structural validity of the HIT-6 and most PROMIS measures. The PROMIS measures showed moderate to strong correlations with theoretically-similar items from the HCV-PRO and MSAS (0.39-0.77). Trends were observed between worse PRO scores and advanced cirrhosis and greater number of comorbidities, lending support for known-groups validity. CONCLUSIONS: The psychometric properties of the HIT-6 and PROMIS measures performed satisfactorily in this large cohort of patients with HCV starting direct acting antiviral therapy. Opportunities exist for further refinement of these PROs. Evaluation of performance over time and in under-represented subgroups is needed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

April 2018

Volume

47

Issue

7

Start / End Page

1001 / 1011

Location

England

Related Subject Headings

  • Young Adult
  • United States
  • Reproducibility of Results
  • Psychometrics
  • Patient Reported Outcome Measures
  • Pain Management
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Evon, D. M., Amador, J., Stewart, P., Reeve, B. B., Lok, A. S., Sterling, R. K., … Fried, M. W. (2018). Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther, 47(7), 1001–1011. https://doi.org/10.1111/apt.14531
Evon, D. M., J. Amador, P. Stewart, B. B. Reeve, A. S. Lok, R. K. Sterling, A. M. Di Bisceglie, et al. “Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.Aliment Pharmacol Ther 47, no. 7 (April 2018): 1001–11. https://doi.org/10.1111/apt.14531.
Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr;47(7):1001–11.
Evon, D. M., et al. “Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.Aliment Pharmacol Ther, vol. 47, no. 7, Apr. 2018, pp. 1001–11. Pubmed, doi:10.1111/apt.14531.
Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr;47(7):1001–1011.
Journal cover image

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

April 2018

Volume

47

Issue

7

Start / End Page

1001 / 1011

Location

England

Related Subject Headings

  • Young Adult
  • United States
  • Reproducibility of Results
  • Psychometrics
  • Patient Reported Outcome Measures
  • Pain Management
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Humans